API foundation
APIs remain the scientific and manufacturing base of the company and a major contributor to global supply.
Company
Four decades of chemistry.
Building the next generation
of global partnerships.
Founded in 1984, Morepen has grown from an API manufacturing base in Himachal Pradesh into a diversified pharmaceutical and healthcare platform. The next chapter builds on that foundation through deeper development, manufacturing and chronic-care capabilities.
0+Years of pharmaceutical experience
0+Countries served
0 KLAPI / CDMO reactor capacity
0Consecutive NIL Form 483 inspections reported
Current installed API/CDMO reactor capacity: 614 KL. Inspection milestone: company disclosure dated 17 April 2026. Site-specific qualification applies.
The company today
A manufacturing foundation.
A broader future.
API manufacturing since 1984–85 at Baddi and Masulkhana, Himachal Pradesh, now extending into CDMO, formulations and medical devices.
CDMO growth
Long-duration development and manufacturing programs are deepening customer relationships and expanding the role of the platform.
Scale & execution
Installed API/CDMO reactor capacity has reached 614 KL, with further phases planned against customer programs and regulatory readiness.
Capability building
Morepen is strengthening complex chemistry, analytical science, drug-product development and future technology platforms.
Our journey
From API beginnings
to a global platform.
Morepen's journey shows a consistent pattern: build scientific depth, earn regulatory credibility, scale manufacturing and extend into new healthcare and development capabilities.
The beginning
API production starts at Masulkhana, establishing Morepen's manufacturing roots.
Public markets
IPO and listing on Indian stock exchanges broaden the company's access to capital.
Scale & regulated markets
Finished-dosage production expands and Loratadine at Masulkhana marks an important USFDA milestone.
Broader healthcare
Dr. Morepen is launched and Montelukast production adds another significant API franchise.
Regulatory depth
Further USFDA and international milestones extend Morepen's regulated-market presence.
Global approvals broaden
USFDA, PMDA and ANVISA milestones strengthen international customer confidence.
Finished dosage in the U.S.
An OTC formulation launch in the U.S. extends the product journey.
Commercial CDMO & integrated development
Commercial CDMO supplies commence, installed API/CDMO reactor capacity reaches 614 KL and the first U.S. ANDA is submitted.
Global quality & regulatory credentials
Regulatory credibility
built over time.
Morepen's manufacturing and quality systems support customers across regulated markets. Regulatory approvals, inspections and registrations remain specific to the applicable site, product and filing.
Responsible manufacturing
ESG as resilience,
continuity and responsibility.
Morepen's approach links environmental performance with compliance, customer expectations and business continuity. During FY26, the company reported investments in zero-liquid-discharge infrastructure, renewable energy, cleaner fuels and resource-efficiency projects.
01
Zero Liquid Discharge / MEE
Multiple-effect evaporator infrastructure supports water treatment, reuse and zero-liquid-discharge objectives at manufacturing operations.
02
Solar energy
A 1.1 MW solar plant was commissioned in December 2025, with further renewable-energy initiatives under evaluation.
03
Cleaner fuels
LPG boiler conversion and a Parali-based biomass boiler form part of the company's lower-emission manufacturing program.
04
Business continuity
Environmental systems, safe operations, quality discipline and resilient infrastructure are treated as part of dependable global supply.
A clear business architecture
One corporate view.
Distinct business stories.
Pharmaceutical development
& manufacturing
API expertise, CDMO partnerships and drug-product development, supported by science, quality and manufacturing.
Healthcare
Businesses
Medical Devices, Rx and OTC retain their own identities, audiences and enquiry routes.
Corporate social responsibility
Creating shared value
in the communities around us.
Morepen's CSR framework focuses on practical, sustained interventions in healthcare, education and skills, environmental stewardship and rural development.
INR 25 millionCSR expenditure reported for FY26
Preventive healthcare & access
Charitable dispensary support, medical camps, health screening drives and awareness programs designed to improve community health and access.
Learning and livelihoods
Scholarships, educational infrastructure and vocational training aimed at improving learning opportunities and employable skills.
Natural-resource stewardship
Community initiatives around environmental awareness, biodiversity, water conservation and sustainable land management.
Stronger local ecosystems
Infrastructure enhancement and livelihood-generation initiatives intended to improve quality of life and economic resilience in rural communities.
Leadership
Continuity.
Accountability.
Executive leadership is presented upfront, while the wider Board, management team and committee structure remain available on demand through the governance links.
Building today. Transforming tomorrow.
A four-decade foundation, an established global API business, a commercially validated CDMO entry and a clear roadmap for scale and capability.